Greenland Mines (NASDAQ: GRML) announced that Innovation, Science and Economic Development Canada has granted a patent covering technology exclusively licensed by the company for Klotho-based gene therapies targeting cognition, memory and neurodegenerative diseases. The patent protects the use of the secreted Klotho (“s-KL”) RNA splice variant in genetic therapies and includes 42 claims covering its synthesis, delivery methods and potential application across multiple neurological disorders, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis.
The company said the Canadian patent expands its intellectual property portfolio for Klotho-based therapeutics and complements previously issued patents in the United States, China and Europe. Greenland Mines added that process development and manufacturing for lead candidate KLTO-101 is scheduled to begin in August 2026, while KLTO-202 has advanced to GMP manufacturing as the company prepares for regulatory interactions later this year. To view the full press release, visit https://ibn.fm/x2pHA.
This patent grant is significant because it strengthens Greenland Mines' intellectual property position in a rapidly evolving field. Klotho is a protein associated with longevity and cognitive function; its gene therapy applications could address major unmet medical needs in neurodegenerative diseases. The patent covers not only the s-KL variant but also methods of delivery, providing a broad protective umbrella that could be valuable for licensing or partnership opportunities.
The advancement of KLTO-101 and KLTO-202 into manufacturing stages indicates the company is moving from research toward clinical readiness. KLTO-202, targeting ALS, is particularly noteworthy given the limited treatment options for that disease. With GMP manufacturing underway, Greenland Mines appears poised to initiate regulatory discussions, potentially accelerating the timeline to first-in-human trials.
Greenland Mines operates two divisions: mining and biotech. The mining division focuses on the Skaergaard Project in southeast Greenland and the Sarfartoq rare earths project, while the biotech division develops Klotho-based therapies. This dual structure provides diversified exposure but also means the biotech success is tied to the company's overall financial health and ability to fund development. The latest news and updates relating to GRML are available in the company’s newsroom at https://ibn.fm/GRML.
Forward-looking statements in this article involve risks and uncertainties. For a discussion of these factors, see the company's filings with the SEC, including the risk factors in its annual report on Form 10-K and quarterly reports on Form 10-Q. Undue reliance should not be placed on forward-looking statements, which are based on information available as of the date hereof. The company undertakes no duty to update this information unless required by law.
